Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:56:41.857Z.
Calculation as of: 2026-10-06T14:56:41.857Z.
Quote observation: 2026-10-06T14:38:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f
PE RATIO
N/A
Market Cap
$39.28M
PE Ratio
N/A
TTM Avg
328.93
3Y Avg
271.56
5Y Avg
151.89
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | $37.23M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $37.06M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.48M | N/A | 14.70 | 37.22 | 37.36 |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.42M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $35.53M | N/A | 241.49 | 241.49 | 115.68 |
| Incannex Healthcare Limited (IXHL)vs › | $39.24M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.28M | N/A | 328.93 | 271.56 | 151.89 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $39.63M | 23.00 | 36.35 | 61.12 | 61.12 |
| Elutia Inc (ELUT)vs › | $34.42M | 0.83 | 1.13 | 1.13 | 1.13 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.87
Forward EPS (Est.)
$-2.07
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
